Neuronet - Efficiently Networking European Neurodegeneration Research

          Newsletter 2 - January 6, 2020

Welcome to the second
issue of the Neuronet newsletter! 

This second newsletter issue provides you with up-to-date insights on the Innovative Medicines Initiative’s (IMI) research efforts to tackle challenges in neurodegeneration.

It is great to see that our collaboration is gaining momentum. We held a highly productive Scientific Coordination Board Meeting which was followed by our annual networking and communication event at the end of October. The videos and presentations from the latter are now publicly available on our website.

We are also busy preparing the first version of an ‘asset map’ that will depict the richness of the IMI Neurodegeneration portfolio in terms of tools and results in a consolidated way.

There is a highlight from the European Prevention of Alzheimer's Dementia project, which has just made the baseline data from its first 500 participants accessible to the scientific community.

This issue also features a spotlight on early-career researchers, focusing on the work of ECRs in industry and academia. We spoke to Tania Fowke and Shahzad Ahmad from Mimetas and Leiden University, respectively, who told us about their work on the ADAPTED project.

Happy reading and start your year well!
Carlos Díaz
Neuronet Project Coordinator
Research Management Partners
Lennert Steukers
Neuronet Project Leader
Associate Director,
Clinical Scientist, Janssen Pharmaceutica NV



Spotlight on early-career investigators: a Neuronet interview with Tania Fowke and Shahzad Ahmad

This interview dives into the world of collaboration between industry and academia using biotechnology to investigate the Alzheimer’s disease risk factor ApoE4.
Read more

EPAD consortium releases its first wave of data

The European Prevention of Alzheimer's Dementia Consortium announced the availability of baseline data from its first 500 research participants (V500.0). It represents the first formal public data release from the EPAD project for use by academic researchers and institutions worldwide.
Read more

Neuronet organises second Scientific Coordination Board meeting

On 23 October (The Hague, Netherlands), Neuronet convened the second meeting of its Scientific Coordination Board coinciding with Alzheimer Europe’s annual Conference.
Read more

AETIONOMY results presented to Innovative Medicines Initative leadership

The key outcomes of AETIONOMY offer the community interesting insights into the potential to differentiate subtypes of neurodegenerative disorders. The project has delivered several computational models to link molecular features to different clinical presentations or outcomes, such as the speed of disease progression.
Read more



Presentations from event on EU research collaboration in Alzheimer’s disease & beyond are now online

Neuronet's annual networking and communication event highlighted Innovative Medicine Initiative projects that work in the area of neurodegeneration research.
The event took place at the Alzheimer Europe Conference in The Hague encompassing 14 presentations as part of four dedicated parallel sessions.
Read more

Neuronet project newsletters

Models Of Patient Engagement for Alzheimer's Disease Newsletter
December 2019 (MOPEAD)

MOPEAD offered the opportunity to talk about the value of timely diagnosis in a compelling way, through constructive scientific, policy and cost efficacy evaluations.
Amyloid imaging to prevent Alzheimer's disease Newsletter
December 2019 (AMYPAD)

AMYPAD celebrates that it has gone beyond its inflexion point, not only because they are in the second half of the recruitment, but, because both studies are recruiting at a wonderful and steady rate.
European Quality In Preclinical Data Newsletter
December 2019 (EQIPD)

This issue introduces videos about the project, features highlights from conferences & marks the launch of the second beta testing phase of EQIPDs new quality system.
European Prevention of Alzheimer's Dementia Newsletter
November 2019 (EPAD)

Find out about the latest highlights and plans securing the projects' future beyond its Innovative Medicines funding period June 2020.

What we are talking about


Our programme is well represented on Twitter with updates from 13 projects. Follow us to stay ahead on news about European neurodegeneration research. We also collaborated on a campaign on social media focussing on on why we do what we do. Check out the hashtag #WeAreNeuronet
Twitter feed


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

Any related content solely reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

          Newsletter 2 - January 6, 2020

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
NEURONET project · 14, rue Dicks · Luxembourg 1417 · Luxembourg

Email Marketing Powered by Mailchimp